Xu Pengliang, Yu Huanming, Bian Hupo, Jia Dan, Li Wenhui, Dong Hongfeng, Peng Xiuhua
Department of Thoracic Surgery, The First People's Hospital of Huzhou, Huzhou, China.
Department of Radiology, The First People's Hospital of Huzhou, Huzhou, China.
Front Immunol. 2025 Feb 10;16:1533651. doi: 10.3389/fimmu.2025.1533651. eCollection 2025.
Neoadjuvant immunotherapy (NIT) is a rapidly emerging paradigm for advanced resectable non-small cell lung cancer (NSCLC). However, there is no bibliometric analysis in this research field.
To analyze the hotspots and trends in the research of NIT for NSCLC and provide a reference for the study of NIT for lung cancer in China.
Retrieve literature related to NIT for NSCLC from Web of Science, PubMed, and Scopus databases up to September 10, 2024. Use CiteSpace and VOSviewer software visualization software to analyze the keywords of country, author, institution, and literature.
There were 1575 references, and the overall annual publication volume showed an upward trend; Forde and Patrick M have published the most articles in the literature. The research hotspots mainly focus on chemotherapy, NIT for NSCLC, immunotherapy, neoadjuvant chemotherapy, pathological reactions, etc.
This is the first bibliometric study comprehensively summarizing NIT's research trends and development in NSCLC. Our bibliometric assessment provides a panoramic view of the research milieu surrounding NIT for NSCLC, encapsulating the present state, evolving trends, and potential future directions, particularly emphasizing the promise of immunochemotherapy.
新辅助免疫治疗(NIT)是晚期可切除非小细胞肺癌(NSCLC)迅速兴起的一种治疗模式。然而,该研究领域尚无文献计量学分析。
分析NSCLC的NIT研究热点与趋势,为我国肺癌的NIT研究提供参考。
从Web of Science、PubMed和Scopus数据库中检索截至2024年9月10日与NSCLC的NIT相关的文献。使用CiteSpace和VOSviewer软件可视化软件分析国家、作者、机构和文献的关键词。
共纳入1575篇参考文献,总体年发表量呈上升趋势;Forde和Patrick M在文献中发表的文章最多。研究热点主要集中在化疗、NSCLC的NIT、免疫治疗、新辅助化疗、病理反应等方面。
这是第一项全面总结NSCLC中NIT研究趋势和发展的文献计量学研究。我们的文献计量学评估提供了NSCLC的NIT研究环境的全景图,涵盖了当前状态、发展趋势和潜在的未来方向,特别强调了免疫化疗的前景。